NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection.
Boers
M
M
Department of Clinical Epidemiology & Biostatistics, Free University Hospital, 1007 MB, Amsterdam, Netherlands. j.wildbret@azvu.nl
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D016595:Misoprostol / Q000627:therapeutic use; D011720:Pyrazoles; D013272:Stomach Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D013449:Sulfonamides / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D016595:Misoprostol; D000068579:Celecoxib